MYOS MYOS RENS Technology Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * ABG WTT-MedAvail Ltd	2. Issuer Name and Ticker or Trading Symbol MedAvail Holdings, Inc. [ MDVL ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    __X__ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) UNIT 3002-3004, 30TH FLOOR, GLOUCESTER TOWER, THE LANDMARK, CENTRAL	3. Date of Earliest Transaction (MM/DD/YYYY) 3/13/2023
(Street) HONG KONG, K3  (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Pre-Funded Warrant (Right to Buy)	$0.001	3/13/2023		P		6818181		3/13/2023 (1)	(2)	Common Stock	6818181	$0.3212	6818181	I	See footnote (3)
Pre-Funded Warrant (Right to Buy)	$0.001	3/13/2023		P		965130		3/13/2023 (1)	(2)	Common Stock	965130	$0.3212	965130	I	See footnote (4)

Explanation of Responses:
(1)	Prior to the Issuer receiving certain required approval of the Issuer's stockholders (the "Requisite Stockholder Approval"), the Pre-Funded Warrant holders may only exercise up to the product of (i) the holder's pro rata portion of the Pre-Funded Warrants and (ii) 16,025,925, which is the number of shares equal to 19.99% of the Issuer's Common Stock outstanding on March 9, 2023.
(2)	The Pre-Funded Warrants do not expire.
(3)	These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership.
(4)	These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
ABG WTT-MedAvail Ltd UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG, K3		X
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG, K3		X
ABG-WTT Global Life Science Capital Partners GP, L.P. UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG, K3		X
ABG-WTT Global Life Science Capital Partners GP Ltd UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG, K3		X
ABG Management Ltd. UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG, K3		X
Yu Fan UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG, K3		X
Ally Bridge MedAlpha Master Fund L.P. 430 PARK AVENUE, 12TH FLOOR, NEW YORK, NY 10022		X
Ally Bridge Group (NY) LLC 430 PARK AVENUE, 12TH FLOOR, NEW YORK, NY 10022		X

Signatures
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. By: ABG-WTT Global Life Science Capital Partners GP, L.P., its general partner By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner By: /s/ Fan Yu, Director		3/15/2023
**Signature of Reporting Person		Date
ABG-WTT Global Life Science Capital Partners GP, L.P. By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner By: /s/ Fan Yu, Director		3/15/2023
**Signature of Reporting Person		Date
ABG-WTT Global Life Science Capital Partners GP Limited By: /s/ Fan Yu, Director		3/15/2023
**Signature of Reporting Person		Date
Ally Bridge MedAlpha Master Fund L.P. By: Ally Bridge MedAlpha General Partner L.P., its general partner By: Ally Bridge MedAlpha GP, LLC, its general partner By: /s/ Fan Yu, Manager		3/15/2023
**Signature of Reporting Person		Date
Ally Bridge Group (NY) LLC By: ABG Management Ltd., its managing member By: /s/ Fan Yu, Director		3/15/2023
**Signature of Reporting Person		Date
ABG Management Ltd. By: /s/ Fan Yu, Director		3/15/2023
**Signature of Reporting Person		Date
ABG WTT-MedAvail Limited By: /s/ Charles Chon, Director		3/15/2023
**Signature of Reporting Person		Date
/s/ Fan Yu		3/15/2023
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.